نتائج البحث - "Ratajczak, Christine K"

1

دورية أكاديمية

Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial

المساهمون: AbbVie

المصدر: International Journal of Clinical Oncology ; volume 28, issue 1, page 163-174 ; ISSN 1341-9625 1437-7772

مصطلحات موضوعية: Oncology, Hematology, General Medicine, Surgery

الإتاحة: https://doi.org/10.1007/s10147-022-02258-xTest

View record in BASE

2

دورية أكاديمية

Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer:Analysis of the VELIA/GOG-3005 trial

المؤلفون: Aghajanian, Carol, Bookman, Michael A., Fleming, Gini F., Swisher, Elizabeth M., Steffensen, Karina D., Friedlander, Michael, Okamoto, Aikou, Jackson, Camille Gunderson, Sullivan, Danielle, Ratajczak, Christine K., Coleman, Robert L.

المصدر: Aghajanian , C , Bookman , M A , Fleming , G F , Swisher , E M , Steffensen , K D , Friedlander , M , Okamoto , A , Jackson , C G , Sullivan , D , Ratajczak , C K & Coleman , R L 2021 , ' Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer : Analysis of the VELIA/GOG-3005 trial ' , Gynecologic Oncology , vol. 162 , no. 2 , pp. 375-381 . https://doi.org/10.1016/j.ygyno.2021.05.031Test

مصطلحات موضوعية: BICR, GOG-3005, Ovarian cancer, PARP inhibitor, Phase 3, VELIA, Veliparib

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/7fe91d69-44bd-48be-9be7-3540a449cfeeTest

الإتاحة: https://doi.org/10.1016/j.ygyno.2021.05.031Test
https://portal.findresearcher.sdu.dk/da/publications/7fe91d69-44bd-48be-9be7-3540a449cfeeTest
https://findresearcher.sdu.dk/ws/files/190556462/Open_Access_Version.pdfTest

View record in BASE

3

دورية أكاديمية

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer:subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

المؤلفون: Ayoub, Jean Pierre, Wildiers, Hans, Friedlander, Michael, Arun, Banu K., Han, Hyo S., Puhalla, Shannon, Shparyk, Yaroslav, Jakobsen, Erik H., Wu, Meijing, Bach, Bruce A., Feng, Dai, Ratajczak, Christine K., Maag, David, Diéras, Véronique

المصدر: Ayoub , J P , Wildiers , H , Friedlander , M , Arun , B K , Han , H S , Puhalla , S , Shparyk , Y , Jakobsen , E H , Wu , M , Bach , B A , Feng , D , Ratajczak , C K , Maag , D & Diéras , V 2021 , ' Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer : subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial ' , ....

مصطلحات موضوعية: BRCA, breast cancer, PARP inhibitor, phase 3, TNBC

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/37624175-479c-40e7-a9ea-b040bad0c3f1Test

الإتاحة: https://doi.org/10.1177/17588359211059601Test
https://portal.findresearcher.sdu.dk/da/publications/37624175-479c-40e7-a9ea-b040bad0c3f1Test
https://findresearcher.sdu.dk/ws/files/196388278/Open_Access_Version.pdfTest

View record in BASE

4

دورية أكاديمية

Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial

المؤلفون: Arun, Banu K., Han, Hyo S., Kaufman, Bella, Wildiers, Hans, Friedlander, Michael, Ayoub, Jean-Pierre, Puhalla, Shannon L., Bell-McGuinn, Katherine M., Bach, Bruce A., Kundu, Madan G., Ratajczak, Christine K., Maag, David, Diéras, Véronique

المصدر: European Journal of Cancer ; volume 154, page 35-45 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/j.ejca.2021.05.037Test
https://api.elsevier.com/content/article/PII:S0959804921003658?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0959804921003658?httpAccept=text/plainTest

View record in BASE

5

دورية أكاديمية

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3):a randomised, double-blind, placebo-controlled, phase 3 trial

المصدر: Diéras , V , Han , H S , Kaufman , B , Wildiers , H , Friedlander , M , Ayoub , J-P , Puhalla , S L , Bondarenko , I , Campone , M , Jakobsen , E H , Jalving , M , Oprean , C , Palácová , M , Park , Y H , Shparyk , Y , Yañez , E , Khandelwal , N , Kundu , M G , Dudley , M , Ratajczak , C K , Maag , D & Arun , B K 2020 , ' Veliparib with ....

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/6f200398-3890-4954-95e6-fe24d6b953a3Test

الإتاحة: https://doi.org/10.1016/S1470-2045Test(20)30447-2
https://hdl.handle.net/11370/6f200398-3890-4954-95e6-fe24d6b953a3Test
https://research.rug.nl/en/publications/6f200398-3890-4954-95e6-fe24d6b953a3Test
https://pure.rug.nl/ws/files/133341802/Veliparib_with_carboplatin_and_paclitaxel_in_BRCA_mutated_advanced_breast_cancer_BROCADE3_a_randomised_double_blind_placebo_controlled_phase_3_trial.pdfTest

View record in BASE

6

دورية أكاديمية

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

المصدر: Coleman , R L , Fleming , G F , Brady , M F , Swisher , E M , Steffensen , K D , Friedlander , M , Okamoto , A , Moore , K N , Efrat Ben-Baruch , N , Werner , T L , Cloven , N G , Oaknin , A , DiSilvestro , P A , Morgan , M A , Nam , J-H , Leath , C A , Nicum , S , Hagemann , A R , Littell , R D , Cella , D , Baron-Hay , S , Garcia-Donas ....

وصف الملف: application/pdf

العلاقة: https://portal.findresearcher.sdu.dk/da/publications/acae948f-8625-4820-bb82-dcae1f3993b0Test

الإتاحة: https://doi.org/10.1056/NEJMoa1909707Test
https://portal.findresearcher.sdu.dk/da/publications/acae948f-8625-4820-bb82-dcae1f3993b0Test
https://findresearcher.sdu.dk/ws/files/161318291/nejmoa1909707.pdfTest

View record in BASE

7

دورية أكاديمية

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

المؤلفون: van der Biessen, Diane A J, Gietema, Jourik A, de Jonge, Maja J A, Desar, Ingrid M E, den Hollander, Martha W, Dudley, Matthew, Dunbar, Martin, Hetman, Robert, Serpenti, Camille, Xiong, Hao, Mittapalli, Rajendar K, Timms, Kirsten M, Ansell, Peter, Ratajczak, Christine K, Shepherd, Stacie Peacock, van Herpen, Carla M L

المصدر: van der Biessen , D A J , Gietema , J A , de Jonge , M J A , Desar , I M E , den Hollander , M W , Dudley , M , Dunbar , M , Hetman , R , Serpenti , C , Xiong , H , Mittapalli , R K , Timms , K M , Ansell , P , Ratajczak , C K , Shepherd , S P & van Herpen , C M L 2018 , ' A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations ....

مصطلحات موضوعية: PARP inhibitor, BRCA, Solid tumor, Ovarian cancer, Homologous recombination deficiency, POLY(ADP-RIBOSE) POLYMERASE INHIBITORS, EPITHELIAL OVARIAN, CARRIERS

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/c0008f03-8d00-4d9a-8012-89ada7cdc840Test

الإتاحة: https://doi.org/10.1007/s10637-017-0551-zTest
https://hdl.handle.net/11370/c0008f03-8d00-4d9a-8012-89ada7cdc840Test
https://research.rug.nl/en/publications/c0008f03-8d00-4d9a-8012-89ada7cdc840Test
https://pure.rug.nl/ws/files/55435622/A_phase_1_study_of_PARP_inhibitor_ABT_767_in_advanced.pdfTest

View record in BASE

8

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer:subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

المؤلفون: Ayoub, Jean-Pierre, Wildiers, Hans, Friedlander, Michael, Arun, Banu K, Han, Hyo S, Puhalla, Shannon, Shparyk, Yaroslav, Jakobsen, Erik H, Wu, Meijing, Bach, Bruce A, Feng, Dai, Ratajczak, Christine K, Maag, David, Dieras, Veronique

المصدر: Ayoub, J P, Wildiers, H, Friedlander, M, Arun, B K, Han, H S, Puhalla, S, Shparyk, Y, Jakobsen, E H, Wu, M, Bach, B A, Feng, D, Ratajczak, C K, Maag, D & Diéras, V 2021, ' Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer : subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial ', Therapeutic Advances in Medical Oncology, vol. 13, pp. 1-13 . https://doi.org/10.1177/17588359211059601Test

مصطلحات موضوعية: DOUBLE-BLIND, PATHOLOGY, Science & Technology, breast cancer, PARP inhibitor, Oncology, PLACEBO, phase 3, CONSORTIUM, BRCA, INHIBITOR, Life Sciences & Biomedicine, TNBC